ANIKA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.63 USD | +1.46% |
|
-7.10% | +13.11% |
| May. 08 | Transcript : Anika Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09 | MT |
Presenter SpeechMark Namaroff (Executives)Welcome, everybody. Good morning. Welcome. My name i...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.63
USD
Average target price
31
USD
Spread / Average Target
+20.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.11% | 380M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Transcript : Anika Therapeutics, Inc. - Analyst/Investor Day
